Dova is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates where there is a high unmet medical need. DOPTELETÂŽ (avatrombopag) is an orally administered thrombopoietin receptor agonist that we are developing for the treatment of thrombocytopenia across many different patient types. Source
No articles found.
Bio-Path is a biotechnology company developing targeted therapies for acute myeloi...
Bio-Path is a biotechnology company developing ...
Agenus is an immuno-oncology company designed to deliver innovation with speed for...
Agenus is an immuno-oncology company designed t...
Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...
Neurocarrus is developing a breakthrough therap...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
Join the National Investor Network and get the latest information with your interests in mind.